Doug Ingram announced on Jun. 16 that he would step down as CEO of Sarepta Therapeutics after more than three decades in the industry, citing a “fairly shocking and ironic twist of fate.” Ingram said his decision was influenced by a recent family diagnosis: two members of his immediate family were afflicted with DM-1, the same disease targeted by Sarepta’s partnership with Arrowhead for the SRP-1003 therapy. Ingram said leaving Sarepta would allow him to focus more on his family.
By year’s end, Sarepta will be under new management, though no replacement has been named yet. The article highlights that Ingram’s experience is not unique in biopharma, where many have been motivated to pursue drug development due to personal or familial diagnoses.
Other examples include Quiver Bioscience in Massachusetts, which received a targeted investment from an Argentinian family office after one member was diagnosed with Dup15q syndrome. José A. Porta, president of the family office, said, “As the father of a daughter living with this condition, this is not an ordinary investment — it is a deeply personal commitment to every family navigating this journey every single day.” The funding will support preclinical activities for Quiver’s antisense oligonucleotide targeting UBE3A.
Solid Biosciences was founded in 2013 by Ilan and Annie Ganot to find a cure for their son Eytani’s Duchenne muscular dystrophy (DMD). At Solid's founding there were no approved therapies for DMD; now its gene therapy SGT-003 is being tested in Phase 1/2 and Phase 3 trials using proprietary vector technology aimed at improving efficacy and safety over existing treatments.
Similarly, Elpida Therapeutics was launched by Terry and Georgia Pirovolakis after their son Michael was diagnosed with SPG50. Their gene therapy MELPIDA showed promising results in Michael—improvements in limb spasticity and motor gains—and has entered Phase 3 development.
John Crowley established Novazyme Pharmaceuticals to develop treatment for Pompe disease affecting his children; after Novazyme's acquisition by Genzyme, he left so his children could participate in clinical trials. The resulting therapy is now marketed as Lumizyme under Sanofi following further corporate acquisitions.
The article also recounts Julia Vitarello's efforts founding EveryONE Medicines after her daughter Mila was diagnosed with Batten disease; despite some improvements from an individualized treatment called milasen developed at Boston Children’s Hospital, Mila died at age ten. Vitarello continues work through Mila’s Miracle Foundation.
Finally, Cure Rare Disease was founded by Rich Horgan aiming to treat his brother Terry's Duchenne muscular dystrophy using CRISPR-based gene therapy tailored specifically for him. Terry died shortly after receiving treatment; research suggested complications arose from the viral vector used.
